A practical reference on tesamorelin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-18 and is reviewed periodically as new material appears.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Another case was that of Ismil bin Kadar, who was initially sentenced to death for a 2005 robbery-murder case in Boon Lay, but eventually acquitted of the crime as the Court of Appeal found that based on the evidence, Ismil was not involved in the case and that it was solely his younger brother Muhammad bin Kadar who was responsible for the robbery and murder; Muhammad was subsequently executed in April 2015. Successful clemency applications are thought to be even rarer. Since 1965, the presidential clemency has been granted seven times to death row inmates, whose sentences were all commuted to life imprisonment (not counting the clemency pleas of the underaged offenders serving TPP). The most recent case was in August 2025, when convicted drug trafficker Tristan Tan Yi Rui was granted clemency by President Tharman Shanmugaratnam, who commuted Tan's death sentence to life imprisonment. Prior to Tan's pardon, the last presidential clemency to be granted was in April 1998, when President Ong Teng Cheong pardoned a 19-year-old death row inmate and convicted murderer Mathavakannan Kalimuthu, commuting his death sentence to life imprisonment. Previously, other than the Court of Appeal, offenders were allowed to file criminal or civil appeals to the Privy Council in London, where the judges could hear their appeals once they exhausted all avenues of appeal in Singapore. This avenue of appeal was fully abolished for all criminal and civil matters in April 1994. One case in which an appeal to the Privy Council was successful was the case of murderer Mohamed Yasin bin Hussin.
=== Medicinal === Like G. lucidum, G. tsugae is purported to have medicinal properties including use for dressing a skin wound. Though phylogenetic analysis has begun to better differentiate between many closely related species of Ganoderma; there is still disagreement as to which have the most medicinal properties. Natural and artificial variations (e.g. growing conditions and preparation) may also affect any medicinal value. Studies in mice have shown that G. tsugae shows several potential medicinal benefits including anti-tumor activity through some of the active polysaccharides found in G. tsugae. G. tsugae has also been shown to significantly promote wound healing in mice as well as markedly increase the proliferation and migration of fibroblast cells in culture.
In 2021, Pansino hosted the HBO Max series Baketopia where contestants competed in a bake-off to win up to $10,000; her hosting work on the show received praise and she also executive produced several episodes. In November 2024, Pansino started her own podcast series called the "Rodiculous Podcast", where she has interviews and conversations with celebrities and fellow YouTubers, with a lot of them being her friends.
The inquiry will have two areas of focus – a review of the "placement and categorisation" of all inmates at Wandsworth, and an investigation of all people in custody currently charged with terror offences. The UK's first EV-only manufacturing plant begins production at Ellesmere Port, Cheshire. The UK experiences a fourth day of temperatures exceeding 30 °C (86 °F), the highest consecutive number on record for the month of September, with hot weather expected to continue until the weekend. 8 September – The first anniversary of the death of Elizabeth II is marked by gun salutes at Hyde Park and the Tower of London, as well as the release of a short message from Charles III along with a previously unreleased portrait of the Queen taken in 1968. 9 September – Following a four-day manhunt, Daniel Khalife is arrested by the Metropolitan Police in Chiswick, London. 10 September The Sunday Times reports that two men have been arrested under the Official Secrets Act, including a researcher in the UK Parliament accused of spying for China. Mo Farah, considered one of the greatest British athletes of all time, takes part in the final race of his career at age 40, finishing fourth in the Great North Run. The Metropolitan Police confirm that Daniel Khalife has been charged with escaping from Wandsworth Prison. He appears before Westminster Magistrates Court the following day, where he is remanded in custody until 29 September. 11 September The GMB Union confirms that the UK's 400 Wilko stores will close by early October after a bid to rescue the retailer fell through.
Sources: en.wikipedia.org
With the invention of the Geiger gaseous ionization detector in 1913, which became the Geiger-Müller gaseous ionization detector in 1928 - named after the physicists Hans Geiger (1882-1945) and Walther Müller (1905-1979) - the individual particles or quanta of ionizing radiation could be detected and measured. Detectors developed later, such as proportional counters or scintillation counters, which not only "count" but also measure energy and distinguish between types of radiation, also became important for radiation protection. Scintillation measurement is one of the oldest methods of detecting ionizing radiation or X-rays; originally, a zinc sulfide screen was held in the path of the beam and the scintillation events were either counted as flashes or, in the case of X-ray diagnostics, viewed as an image. A scintillation counter known as a spinthariscope was developed in 1903 by William Crookes (1832-1919) and used by Ernest Rutherford (1871-1937) to study the scattering of alpha particles from atomic nuclei.
The primary function of the corticotropic cells is to produce the prohormone POMC in response to the release of CRH from the hypothalamus. POMC is cleaved into several peptide hormones via enzyme activity. In addition to synthesis in the corticotropes, POMC is also synthesized in melanotroph cells, the arcuate nucleus of the hypothalamus, and melanocytes. POMC undergoes differential cleavage into various peptide hormones depending on the cell it is synthesized in; it also varies based on species. POMC in the corticotropes of humans is proteolytically cleaved by proprotein convertases into ACTH and β-lipotropin. In rats, however, the ACTH is further cleaved into α-MSH and CLIP in the corticotrope. These peptide hormones are stored within vesicles in the corticotropic cells and are released in response to CRH stimulation from the hypothalamus. These vesicles then leave the anterior pituitary and travel throughout the body via the bloodstream to reach their target tissues.
=== Other polymers === Other sugar polymers include vegetable gums such as pectin from Citrus peel, guar gum from the guar bean, and locust bean gum from the carob bean. Agar, alginin and carrageenan are polysaccharides extracted from algae, xanthan gum is a polysaccharide secreted by the bacterium Xanthomonas campestris, and carboxymethyl cellulose is a synthetic gum derived from cellulose. Proteins used as food thickeners include collagen, egg whites, and gelatin. Other thickening agents act on the proteins already present in a food; for example sodium pyrophosphate, which acts on casein in milk during the preparation of instant pudding.
Factor VIII is bound to VWF while inactive in circulation; factor VIII degrades rapidly when not bound to VWF. Factor VIII is released from VWF by the action of thrombin. In the absence of VWF, factor VIII has a half-life of 1–2 hours; when carried by intact VWF, factor VIII has a half-life of 8–12 hours. VWF binds to collagen, e.g., when collagen is exposed beneath endothelial cells due to damage occurring to the blood vessel. Endothelium also releases VWF which forms additional links between the platelets' glycoprotein Ib/IX/V and the collagen fibrils VWF binds to platelet GpIb when it forms a complex with gpIX and gpV; this binding occurs under all circumstances, but is most efficient under high shear stress (i.e., rapid blood flow in narrow blood vessels, see below). VWF binds to other platelet receptors when they are activated, e.g., by thrombin (i.e., when coagulation has been stimulated). VWF plays a major role in blood coagulation. Therefore, VWF deficiency or dysfunction (von Willebrand disease) leads to a bleeding tendency, which is most apparent in tissues having high blood flow shear in narrow vessels. From studies it appears that VWF uncoils under these circumstances, decelerating passing platelets. Recent research also suggests that von Willebrand Factor is involved in the formation of blood vessels themselves, which would explain why some people with von Willebrand disease develop vascular malformations (predominantly in the digestive tract) that can bleed excessively.
==== Type II ==== Collagen is fatally defective at its C-terminus. Most cases result in death shortly after birth, or within the first year of life, due to respiratory failure. Another common cause of death is intracranial bleeds from skull fractures present at, or sustained during or shortly after, birth. In many cases, the newborn already has multiple broken bones at the time of birth. Type II infants also exhibit severe respiratory problems and have severely deformed bones. Sixty percent of infants die less than 24 hours after being born, and survival after the first year is extremely unlikely and normally requires mechanical ventilation. In the rare cases of infants who survive their first year of life, severe developmental and motor delays are seen; neither of two infants studied in 2019, both aged around two years, had achieved head control, and both required a ventilator to breathe. Type II is also known as the "lethal perinatal" form of OI, and is not compatible with survival into adulthood. Due to similarly severely deformed bones, sometimes infants with severe type III are wrongly initially classified as type II; once long-term survival is shown, they are considered as having type III instead.
Sources: en.wikipedia.org
The shear strength between two collagen molecules is controlled by weak dispersive and hydrogen bond interactions and by some molecular covalent crosslinks. Slip in the system occur when these intermolecular bonds face an applied stress greater than their interaction strength. Intermolecular bonds breaking do not immediately lead to failure, in contrast they play an essential role in energy dissipation that lower the stress felt overall by the material and enable it to withstand fracture. These bonds, often hydrogen bonding and dispersive Van der Waals interactions, act as "sacrificial" bonds, existing for the purpose of lowering stress in the network. Molecular covalent crosslinks also play a key role in the formation of fibril networks. While crosslinking molecules can lead to strong structures, too much crosslinking in biopolymer networks are more likely to fracture as the network is not able to dissipate the energy, leading to a material that is strong but not tough. This is observed in dehydrated or aged collagen, explaining why with age human tissues become more brittle. Differences in structure between fibrils of different origin is typically determined by x-ray diffraction. A scanning electron microscope (SEM) can be used to observe specific details on larger fibril species such as the characteristic 67 nm bands in collagen, but often is not fine enough to determine the full structure.
Promethium forms only one stable oxidation state, +3, in the form of ions; this is in line with other lanthanides. Promethium can also form the +2 oxidation state. Thermodynamic properties of Pm2+ suggests that the dihalides are stable, similar to NdCl2 and SmCl2.
The advent of insulin analogs and continued use of NPH insulin led to the discontinuation of ultralente insulin products in the mid-2000s, and FDA approval to be marketed in the US was withdrawn by 2011.
A nonsynonymous substitution results in a change in amino acid that may be arbitrarily further classified as conservative (a change to an amino acid with similar physiochemical properties), semi-conservative (e.g. negatively to positively charged amino acid), or radical (vastly different amino acid).
=== Affinity Chromatography === Affinity chromatography exploits the specific interactions between proteins and their ligands. A target protein is captured on a column containing a ligand that specifically binds to it, such as an antibody, enzyme substrate, or metal ion. After washing away non-specifically bound proteins, the target protein is eluted using a solution that disrupts the protein-ligand interaction. This method provides high specificity and is often used for purifying recombinant proteins that have affinity tags.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.